In early studies, our innovative test matched the actual responses of more than 80% of treatments. Our evidence is growing through multiple clinical research studies with major medical institutions throughout the United States.
Peer-reviewed Papers
JCO Precision Oncology*
Next-generation ex vivo approaches, such as the RapidSelection™ technology, offer an alternative precision medicine approach for a broad population of patients with cancer.
Nature’s Communications Biology*
The paper describes how our technology offers a promising complement to genomics-based cancer therapy guidance by testing drug efficacy directly on a patient’s tumor cells.
Leading Institutions
The institutions involved in our clinical studies include:
